GAMMA Investing LLC Grows Position in Ascendis Pharma A/S (NASDAQ:ASND)

GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 15,593.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,490 shares of the biotechnology company's stock after acquiring an additional 90,907 shares during the period. GAMMA Investing LLC owned about 0.15% of Ascendis Pharma A/S worth $142,600,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ASND. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth about $28,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares during the last quarter. Quarry LP bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth about $96,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. The Goldman Sachs Group lifted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $180.00 to $250.00 in a research note on Monday, May 5th. Finally, Wedbush lifted their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $216.73.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded up $3.86 during trading on Thursday, reaching $177.55. 358,045 shares of the stock were exchanged, compared to its average volume of 490,779. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The stock has a fifty day moving average of $158.52 and a two-hundred day moving average of $146.15. The firm has a market cap of $10.83 billion, a price-to-earnings ratio of -25.01 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.